HealthShares Announces Changes to the HealthShares Infectious Disease, Respiratory/Pulmonary, Cancer, and Composite Indexes
NEW YORK, May 31, 2007 /PRNewswire/ -- HealthShares(TM) Inc., an investment company with a series of 20 underlying fund portfolios, today announced it has been informed by Standard & Poor's, the calculating agent for the HealthShares(TM) Indexes, that effective at the opening of trading on Tuesday June 5, 2007, Solvay SA (SOLB. Brussels) will replace Medimmune Inc. (MEDI) in the HealthShares(TM) Infectious Disease Index; UCB SA (UCB. Brussels) will replace Medimmune in the HealthShares(TM) Respiratory/Pulmonary Index; and Fresenius SA (FME. Germany) will replace Medimmune in the HealthShares(TM) Cancer Index and the HealthShares(TM) Composite Index. Medimmune is being acquired by U.K. based AstraZeneca PLC.
Companies included in the Infectious Disease Index are engaged in the research, clinical development and/or commercialization of therapeutic agents for the treatment of a wide variety of infectious diseases related to antibacterial, antifungal and antiviral indications, by means of small molecules, protein therapy and vaccines.
Companies included in the Respiratory/Pulmonary Index are engaged in the research, development, and/or commercialization of therapeutic agents treating various respiratory and/or pulmonary diseases including, but not limited to, asthma, chronic obstructive pulmonary disease, emphysema, tuberculosis and pulmonary arterial hypertension.
Companies included in the Cancer Index are engaged in the research, clinical development and/or commercialization of therapeutic agents for the treatment of a wide variety of cancers. Companies in this index generally include those with substantial revenues and significant research and development programs.
XShares Advisors LLC, a financial services company based in New York, is the creator of the HealthShares(TM) family of Exchange Traded Funds (ETFs). HealthShares(TM) ETFs are organized into therapeutic 'Verticals' and represent specific areas of the healthcare, life science and biotechnology industries. Each Vertical addresses a distinct sub-segment of healthcare, such as the diagnosis and treatment of specific therapeutic areas (e.g. cardiology, cancer, infectious disease, etc.) and the development of medical devices (e.g. orthopedic repair, cardio devices, etc.). Each ETF tracks an index of 22-25 stocks and 2 offers institutional and individual investors a more precise financial instrument that leverages the potential of healthcare investing while mitigating the risks of single stock picking. For more information, visit the company's website at: www.healthsharesinc.com.
XShares Advisors LLC, a subsidiary of XShares Group LLC, is a registered investment advisor that provides investment advisory services to Exchange Traded Funds. XShares also partners with major institutions and index providers seeking to bring innovative Exchange Traded Funds to market using its administrative platform. In addition, XShares creates and licenses distinctive intellectual property for its ETFs, developing products that allow for innovative trading strategies and alternative investments for the financial community. For more information, visit the company's website at www.xsharesadvisors.com.
An Investor should consider the fund's investment objective, risks, charges and expenses carefully before investing. For this and more complete information about the fund call 800.925.2870 or visit the website www.healthsharesinc.com for a prospectus. Please read the prospectus carefully before investing.
There are risks involved with investing in ETFs including possible loss of money. HealthShares(TM) are not actively managed and are subject to risks similar to stocks, including those related to short selling and margin maintenance. Losses from short sales may be unlimited, and losses from purchases on margin may exceed original investment. HealthShares(TM) ETFs are subject to increased risks associated with investing in a specific sector compared to a more diversified investment, as well as unique risks associated with the healthcare and biotechnology sector (i.e., government regulation, patent regulation, etc.).
The ETFs face additional risks attributable to their investments in small and medium capitalization companies which are subject to higher volatility than larger, more established companies. In addition, they are invested in a limited number of securities and a decline in the value of these investments would cause the fund's overall value to decline to a greater degree than in a less concentrated portfolio.
Global or International Funds invest in foreign securities that may be subject to certain risks not associated with domestic securities, such as currency fluctuations, and changes in political and economic conditions.
The prospectus is not an offer to buy or sell the portfolio shares, nor is the fund soliciting an offer to buy its shares in any jurisdiction where the offer or sale is not permitted.
HealthShares(TM) Exchange Traded Funds are distributed by ALPS Distributors, Inc.
HSI 252 exp. 6/30/07
CONTACT: Melissa Kanter of Edelman for XShares, +1-212-704-8261, email@example.com
Terms and conditions of use apply
Copyright © 2007 PR Newswire Association LLC. All rights reserved.
A United Business Media Company
Posted: May 2007